Skip to Main Content
Phase Device Pilot

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

  • Study HIC#:2000038498
  • Last Updated:07/23/2025

The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Sophia Kujawski

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    Trial Purpose and Description

    This prospective single-arm pilot study will assess the feasibility of a 6-week at-home light therapy intervention for CIPN. Survivors of childhood cancer (<21 years at diagnosis), ages five years or older at the time of survivorship clinic visit, with a history of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN, will be included if they have CIPN (defined as a score of four or higher on the pediatric modified Total Neuropathy Score for survivors <18 years old at evaluation, or the modified Total Neuropathy Score for survivors 18 years or older at evaluation). The primary outcome of the study will be feasibility of the at-home protocol, measured as proportion of survivors who complete at least 12 at-home light therapy sessions, with ≥70% of survivors completing 12 or more sessions indicating feasibility. Secondary outcomes include 1) Proportion of survivors satisfied with intervention, measured as a mean score of 3 or higher on a 4-point Likert-scale survey 2) Facilitators and barriers to implementation of light-therapy, assessed by semi-structured qualitative interviews with 5-10 survivors who adhered and did not adhere to the protocol, and 3) change in neuropathy symptoms (measured by change in modified Total Neuropathy Score or pediatric-modified Total Neuropathy Score, and gait speed) from baseline to 1 week post intervention.

    Eligibility Criteria

    Inclusion Criteria:

    • History of childhood cancer (<21 years of age at diagnosis)
    • Current age five years or older (due to availability of validated measures for CIPN in this age group)
    • History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN
    • CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors <18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)

    Exclusion Criteria:

    • Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)
    • Inability to sit still for at least 15 minutes
    • Diagnosis of neuropathy prior to cancer treatment
    • Active cancer diagnosis or cancerous skin lesion
    • Central nervous system tumor (due to lack of validated measures for CIPN in this population)
    • Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.

    Principal Investigator

    For more information about this study, including how to volunteer, contact: